C4 Therapeutics (CCCC) Cash from Financing Activities (2019 - 2026)
C4 Therapeutics (CCCC) posted quarterly Cash from Financing Activities of $462000.0 for Q1 2026, up 1104.35% year-over-year from $38361.0 in Q1 2025, and down 99.61% quarter-over-quarter from $118.7 million in Q4 2025.
C4 Therapeutics (CCCC) Cash from Financing Activities (2019 - 2026) Analysis & Trends
C4 Therapeutics' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $462000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 1104.35% year-over-year to $462000.0; the TTM figure through Mar 2026 stood at $126.9 million (up 1085.27% YoY), while the FY2025 annual figure was $126.4 million, up 178.8% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $462000.0, down from $118.7 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $118.7 million in Q4 2025, with the low at -$10.8 million in Q3 2023.
- The 5-year median for Cash from Financing Activities is $310000.0 (2022), against an average of $13.7 million.
- Peak annual rise in Cash from Financing Activities reached 122606.38% in 2023, while the deepest fall reached 3078.67% in 2023.
- C4 Therapeutics' Cash from Financing Activities stood at $47000.0 in 2022, then surged by 122606.38% to $57.7 million in 2023, then tumbled by 99.81% to $112000.0 in 2024, then jumped by 105857.14% to $118.7 million in 2025, then sank by 99.61% to $462000.0 in 2026.
- Business Quant data shows CCCC's Cash from Financing Activities at $462000.0 in Q1 2026, $118.7 million in Q4 2025, and $7.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - | 33.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.73 Mn |
| Jun 30, 2026 | 33.73 Mn |
| Mar 31, 2026 | 462,000.00 |
| Mar 31, 2026 | 462,000.00 |
| Dec 31, 2025 | 118.67 Mn |
| Dec 31, 2025 | 118.67 Mn |
| Sep 30, 2025 | 7.77 Mn |
| Sep 30, 2025 | 7.77 Mn |
| Mar 31, 2025 | -46,000.00 |
| Mar 31, 2025 | -46,000.00 |
| Dec 31, 2024 | 112,000.00 |
| Dec 31, 2024 | 112,000.00 |
| Sep 30, 2024 | 10.51 Mn |
| Sep 30, 2024 | 10.51 Mn |
| Jun 30, 2024 | 135,000.00 |
| Jun 30, 2024 | 135,000.00 |
| Mar 31, 2024 | 34.58 Mn |
| Mar 31, 2024 | 34.58 Mn |
| Dec 31, 2023 | 57.67 Mn |
| Dec 31, 2023 | 57.67 Mn |